{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:52:39Z","timestamp":1787737959115,"version":"build-2784847793"},"reference-count":13,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2012,1,25]],"date-time":"2012-01-25T00:00:00Z","timestamp":1327449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Aromatase inhibitors (AIs) are routinely used as first-line adjuvant treatment of breast cancer in postmenopausal women with hormone receptor positive tumors. The current recommended length of treatment with an AI is 5 years. Arthralgias have been frequently cited as the primary reason for discontinuation of AI therapy. Various treatment strategies are proposed in literature, but a standardized treatment algorithm has not been established. The initial purpose of this study was to describe the incidence and management of AI-induced arthralgias in patients treated at Kellogg Cancer Center (KCC). Further evaluation led to the development and the implementation of a treatment algorithm and electronic medical record (EMR) documentation tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The retrospective chart review included 206 adult patients with hormone receptor positive breast cancer who were receiving adjuvant therapy with an AI. A multidisciplinary treatment team consisting of pharmacists, collaborative practice nurses, and physicians met to develop a standardized treatment algorithm and corresponding EMR documentation tool. The treatment algorithm and documentation tool were developed after the study to better monitor and proactively treat patients with AI-induced arthralgias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/conclusions:<\/jats:title>\n                    <jats:p>The overall incidence of arthralgias at KCC was 48% ( n\u2009=\u200998\/206). Of these patients, 32% were documented as having arthralgias within the first 6 months of therapy initiation. Patients who reported AI-induced arthralgias were younger than patients who did not report AI-induced arthralgias (61 vs. 65 years, p\u2009=\u20090.002). There was no statistical difference in the incidence of arthralgias in patients with a history of chemotherapy (including taxane therapy) compared to those who did not receive chemotherapy ( p\u2009=\u20090.352). Of patients presenting with AI-induced arthralgias, 41% did not have physician-managed treatment documented in the EMR. A standardized treatment algorithm and electronic chart documentation tools were then developed by the multidisciplinary team.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155211434853","type":"journal-article","created":{"date-parts":[[2012,1,25]],"date-time":"2012-01-25T22:43:42Z","timestamp":1327531422000},"page":"387-393","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic"],"prefix":"10.1177","volume":"18","author":[{"given":"Pamela","family":"Menas","sequence":"first","affiliation":[{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"},{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Merkel","sequence":"additional","affiliation":[{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"},{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Hui","sequence":"additional","affiliation":[{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"},{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lawton","sequence":"additional","affiliation":[{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"},{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Harper","sequence":"additional","affiliation":[{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"},{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Carro","sequence":"additional","affiliation":[{"name":"Kellogg Cancer Center, NorthShore University Health System, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,1,25]]},"reference":[{"key":"bibr1-1078155211434853","unstructured":"American Cancer Society. \u2018How many women get breast cancer?\u2019, http:\/\/www.cancer.org (accessed June 2011)."},{"key":"bibr2-1078155211434853","unstructured":"WebMD. \u2018Types of breast cancer: ER Positive, HER2 positive, and triple negative\u2019, http:\/\/www.webmd.com\/breast-cancer\/breast-cancer-types-er-positive-her2-positive (accessed April 2010)."},{"key":"bibr3-1078155211434853","doi-asserted-by":"publisher","DOI":"10.3747\/co.v16i0.457"},{"key":"bibr4-1078155211434853","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4005"},{"key":"bibr5-1078155211434853","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.10.004"},{"key":"bibr6-1078155211434853","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7684"},{"key":"bibr7-1078155211434853","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24419"},{"key":"bibr8-1078155211434853","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.7573"},{"key":"bibr9-1078155211434853","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70182-7"},{"issue":"10","key":"bibr10-1078155211434853","first-page":"1171","volume":"49","author":"Hess D","year":"2004","journal-title":"Respir Care"},{"issue":"9324","key":"bibr11-1078155211434853","first-page":"2131","volume":"349","author":"The ATAC Trialists\u2019 Group","year":"2002","journal-title":"The Lancet"},{"key":"bibr12-1078155211434853","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70259-6"},{"key":"bibr13-1078155211434853","unstructured":"CTCAE. Common terminology criteria for adverse events v 3.0, National Institutes of Health, National Cancer Institute, August 2006."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155211434853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155211434853","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155211434853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:28Z","timestamp":1777688068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155211434853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,25]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1177\/1078155211434853"],"URL":"https:\/\/doi.org\/10.1177\/1078155211434853","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,25]]}}}